The ASH 2024 conference news includes Johnson & Johnson seeking approval for a treatment for smoldering myeloma, GSK’s promising results for Blenrep in multiple myeloma, efforts to ease conditioning in genetic treatments for sickle cell disease, and Kura Oncology’s positive Phase 1 trial results for AML. Pfizer’s withdrawal of Oxbryta for sickle cell disease raised questions at a meeting, with no clear answers yet. The conference also discussed the debate around treating smoldering myeloma early and the potential for menin inhibitors in AML treatment. Future editions of ASH news can be accessed by signing up for the newsletter.
Source link
Roundup of news from the third day of the conference
